Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab.
BMJ Case Rep
; 14(1)2021 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1015618
ABSTRACT
As of 28 October 2020, there are over 44 000 000 confirmed COVID-19 infections and over 1 000 000 deaths worldwide, including 945 367 infections and 45 765 deaths in the UK. Acute respiratory distress syndrome occurs in 50% of patients with secondary haemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome characterised by a surge of cytokines, including interleukin 6 (IL-6). Here we describe the case of the first patient with severe COVID-19 pneumonia successfully treated with tocilizumab, a humanised monoclonal antibody against the IL-6 receptor, in the UK. Early treatment (after 7-10 days from the onset of symptoms) with tocilizumab could (1) reduce the risk of requiring non-invasive or invasive ventilation; (2) offer a chance of survival to people who are not fit for escalation or have refused to be ventilated; and (3) potentially increase the chance of survival in some patients who are already ventilated but fail to improve with supportive treatment.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Monoclonales Humanizados
/
Tratamiento Farmacológico de COVID-19
/
Hipoxia
Tipo de estudio:
Reporte de caso
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Anciano
/
Humanos
/
Masculino
Idioma:
Inglés
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Bcr-2020-238210
Similares
MEDLINE
...
LILACS
LIS